ALPRAZOLAM TABLET
Land: Canada
Sprog: engelsk
Kilde: Health Canada
Produktets egenskaber
(SPC)
06-06-2019
Nogle dokumenter til dette produkt er ikke tilgængelige i øjeblikket, du kan sende en anmodning til vores kundeservice, og vi vil underrette dig, så snart vi er i stand til at få dem.
Send anmodning.
Send anmodning.
Aktiv bestanddel:
ALPRAZOLAM
Tilgængelig fra:
SANIS HEALTH INC
ATC-kode:
N05BA12
INN (International Name):
ALPRAZOLAM
Dosering:
0.25MG
Lægemiddelform:
TABLET
Sammensætning:
ALPRAZOLAM 0.25MG
Indgivelsesvej:
ORAL
Enheder i pakken:
100
Recept type:
Targeted (CDSA IV)
Terapeutisk område:
BENZODIAZEPINES
Produkt oversigt:
Active ingredient group (AIG) number: 0115008001; AHFS:
Autorisation status:
CANCELLED POST MARKET
Autorisation dato:
2021-12-01
Produktets egenskaber
PRODUCT MONOGRAPH
ALPRAZOLAM
(Alprazolam)
0.25 mg and 0.5 mg Tablets
USP
ANXIOLYTIC - ANTIPANIC
Sanis Health Inc.
Date of Revision:
1 President’s Choice Circle,
June 6, 2019
Brampton, Ontario
L6Y 5S5
www.sanis.com
Control No.: 228154
2
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................. 3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
3
CONTRAINDICATIONS
...............................................................................................................
5
WARNINGS AND PRECAUTIONS
..............................................................................................
5
ADVERSE REACTIONS
..............................................................................................................
12
DRUG INTERACTIONS
..............................................................................................................
16
DOSAGE AND ADMINISTRATION
..........................................................................................
19
OVERDOSAGE
.............................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
........................................................................
21
STORAGE AND STABILITY
......................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................... 23
PART II: SCIENTIFIC INFORMATION
...................................................................................
24
PHARMACEUTICAL
INFORMATION......................................................................................
24
CLINICAL TRIALS
...............................................................................
Læs hele dokumentet
